

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)



(10) International Publication Number
WO 2024/032561 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) A61K 31/505 (2006.01)
C07D 471/12 (2006.01) A61K 31/519 (2006.01)
C07D 487/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2023/111521

(22) International Filing Date:

07 August 2023 (07.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/110858
08 August 2022 (08.08.2022) CN
PCT/CN2022/130631
08 November 2022 (08.11.2022) CN
PCT/CN2023/080498
09 March 2023 (09.03.2023) CN
PCT/CN2023/083161
22 March 2023 (22.03.2023) CN
PCT/CN2023/107019
12 July 2023 (12.07.2023) CN

(71) Applicant: **INSILICO MEDICINE IP LIMITED**
[CN/CN]; 26th Floor, Three Exchange Square, 8 Connaught
Place Central, Hong Kong (CN).

(72) Inventors: **LU, Hongfu**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **LIU, Yingtao**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **WU, Jianping**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **ZHENG, Min**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN). **REN, Feng**; Suite 901, Tower C, Chang-
tai Plaza, 2889 Jinke Road, Pudong New Area, Shanghai
201203 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY
LAW OFFICE**; Tower B, 21st Fl. Suite 2108, 38 Xueqing
Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF




FIG. 1A

(57) Abstract: Described herein are inhibitors of cyclin-dependent kinase (CDK) 12 and/or CDK13 (and pharmaceutical compositions comprising the inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with overexpression of CDK 12 and/or CDK13.

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))